Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma

Tamer Khashab, Fredrick Hagemeister, Jorge E. Romaguera, Michelle A. Fanale, Barbara Pro, Peter McLaughlin, M. Alma Rodriguez, Sattva S. Neelapu, Luis Fayad, Anas Younes, Lei Feng, Francisco Vega, Larry W. Kwak, Felipe Samaniego*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science